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The sulfated glycosaminoglycan heparan sulfate (HS)
is found ubiquitously on cell surfaces, in the extracellu-
lar matrix, and intracellularly as HS proteoglycans. Be-
cause of the structural heterogeneity of HS, tissue-de-
rived HS preparations represent a mixture of HS chains
originating from different cell types and tissue loci.
Monoclonal anti-HS antibodies have been employed to
detect the localization of specific HS epitopes in tissues,
but limited information has been available on the sac-
charide structures recognized by the antibodies. We
have studied the saccharide epitope structures of four
anti-HS antibodies, HepSS1, JM13, JM403, and 10E4,
which all recognize distinct HS species as demonstrated
by different patterns of immunoreactivity upon staining
of embryonic rat and adult human tissues. The epitopes
recognized by JM13 and HepSS1 were found almost ex-
clusively in basement membrane HS, whereas JM403
and 10E4 reacted also with cell-associated HS species.
The binding of HepSS1, JM403, and 10E4 to HS was
dependent on the GlcNN-substitution of the polysaccha-
ride rather than O-sulfation. HepSS1 thus interacted
with N-sulfated HS domains, JM403 binding was criti-
cally dependent on N-unsubstituted GlcN residues, and
10E4 bound to “mixed” HS domains containing both N-
acetylated and N-sulfated disaccharide units. By con-
trast, JM13 binding seemed to require the presence of
2-O-sulfated glucuronic acid residues.
Heparan sulfate (HS)1 proteoglycans on cell surfaces and in
the extracellular matrix are implicated in developmental, re-
generative, and pathological processes because of their inter-
actions with multiple proteins (1–5). These interactions are
mediated mainly via the HS components of the proteoglycans,
which bind to growth factors/cytokines, matrix components,
enzymes, and enzyme inhibitors and thereby regulate the tis-
sue localization and biological activities of the proteins. Char-
acterization of HS oligosaccharides with affinity to proteins
such as antithrombin (6) and peptide growth factors (7) has led
to identification of specialized protein binding HS domains
with ligand-specific structural distinctions. These functional
domains derive from enzymatic modification in the Golgi ap-
paratus of the primary polymerization product of HS/heparin
biosynthesis, composed of alternating glucuronic acid and N-
acetylglucosamine units ((GlcUA-GlcNAc)n). The nascent poly-
mer is first subject to partialN-deacetylation/N-sulfation of the
GlcNAc residues. The modification occurs in a regioselective
fashion, giving rise to (i) consecutively N-sulfated regions, (ii)
regions of alternating N-acetylated and N-sulfated disaccha-
ride units, and (iii) domains that escape modification and re-
main N-acetylated (5, 8). Sometimes, the N-deacetylation/N-
sulfation reaction remains partial, with N-unsubstituted GlcN
units as a result (9, 10). The further modification reactions, C5
epimerization of GlcUA residues into iduronic acid (IdoUA)
residues and O-sulfation, all occur in the vicinity of previously
incorporated N-sulfate groups. O-Sulfation is frequently found
at C2 of IdoUA units and at C6 of GlcN units. Rarely, O-
sulfation occurs also at C2 of GlcUA units and at C3 of Glc-
NSO3 residues, the latter sulfate substitution providing a hall-
mark for the antithrombin binding HS/heparin sequence.
In tissues, spatially and temporally coordinated expression
of protein binding HS domains might entail mechanisms to
control the protein activity above the level of protein expres-
sion. Remarkable specificity has indeed been demonstrated
with regard to the ability of HS to form complexes with fibro-
blast growth factors (FGFs) and FGF receptors in mouse embryo
tissues (11), presumably because of structural distinctions be-
tween the HS species found in the distinct tissue loci. Moreover,
immunohistochemical studies of tissues with antibodies against
different HS epitopes suggest structural differences in HS in
distinct cellular environments, such as the tubular and glomer-
ular epithelia and basement membranes of the kidney (12, 13).
Antibodies have become important tools to assess the occur-
rence and localization of HS in tissues. Potentially, antibodies
can also provide structural information of tissue HS, but proper
assessment of such data obviously requires sufficient knowl-
edge of the antibody epitope structure. So far, relatively few
anti-HS antibodies have been studied with regard to their
cognate epitopes. We have previously characterized the epitope
to antibody JM403 (12), in which the key determinant appears
to be an N-unsubstituted GlcN residue (GlcNH3
 or “free amino
* This work was supported by the Academy of Finland Grants 78400
and 20688, the Sigrid Juse´lius Foundation, Finnish cancer organiza-
tions, K. Albin Johanssons Stiftelse, Polysackaridforskning AB, and the
Mizutani Foundation for Glycoscience. The costs of publication of this
article were defrayed in part by the payment of page charges. This
article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
‡‡ To whom correspondence should be addressed: Turku Centre for
Biotechnology, University of Turku and Åbo Akademi University,
Tykisto¨katu 6, FIN-20520 Turku, Finland. Tel.: 358-2-333-8649; Fax:
358-2-333-8000; E-mail: markku.salmivirta@btk.fi.
1 The abbreviations used are: HS, heparan sulfate; CHO, Chinese
hamster ovary; EHS, Englebreth-Holm-Schwarz; ELISA, enzyme-
linked immunosorbent assay; FACS, fluorescence-activated cell sorter;
FGF, fibroblast growth factor; GlcUA, glucuronic acid; HEK, human
embryonic kidney; IdoUA, iduronic acid; K5PS, capsular polysaccharide
from E. coli K5; NDST, N-deacetylase/N-sulfotransferase; OST, O-sul-
fotransferase; PBS, phosphate-buffered saline.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 280, No. 21, Issue of May 27, pp. 20516–20523, 2005
© 2005 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org20516
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
group”). More recently, characterization of the epitopes recog-
nized by the antibody 10E4 (14) and a panel of 10 anti-HS
antibodies constructed by the phase display technology (13)
have been reported. The 10E4 epitope, occurring in multiple
HS species but enriched in the brain lesions of scrapie-infected
mice, has been proposed to encompass a tetrasaccharide se-
quence with an essential GlcNH3
 residue (15). The phage
display antibodies recognized a number of different epitopes
that were all characterized by the presence of N- and O-sulfate
substituents both in HS and heparin preparations (13).
We have studied two previously uncharacterized epitopes to
monoclonal antibodies against HS, JM13 (16) and HepSS1 (17),
and attempted to define further the epitopes recognized by
JM403 and 10E4. Two of the antibodies (10E4 and HepSS1) are
commercially available and have been widely used as research
reagents. Moreover, we have examined the immunoreactivity
of these antibodies in rat and human tissue. Our results sug-
gest that HepSS1 and JM13 bind to rare saccharide epitopes
that occur predominantly in basement membrane HS. HepSS1
reacts specifically with an epitope of several consecutive N-
sulfated disaccharide units with little or no O-sulfation,
whereas JM13 binds to an O-sulfated epitope containing GlcUA.
10E4 and JM403 both recognize more common but distinct
epitopes. Our results suggest a mixed N-sulfated and N-acety-
lated epitope for 10E4 and support the earlier data (12) indicat-
ing a critical role for GlcNH3
 residues in JM403 binding.
MATERIALS AND METHODS
Glycosaminoglycans
HS (preparation HS-II) isolated from human aorta essentially ac-
cording to Iverius (18) was provided by Dr. W. Murphy (University of
Monash, Melbourne, Australia). Chemical modifications to HS-II
(cleavage with HNO2 at pH 1.5 or 3.9, N-deacetylation, N-acetylation,
or N-sulfation) were made as described previously (12). HS prepara-
tions from bovine aorta, lung, intestine, and kidney and the murine
Englebreth-Holm-Schwarz tumor (EHS-HS) were isolated and charac-
terized as described before (19, 20). The chemically modified derivatives
of bovine kidney HS were provided by Dr. A. Tawada (Seikagaku Corp.).
The Escherichia coli K5 capsular polysaccharide (K5PS) with the same
(GlcUA-GlcNAc)n structure as the HS/heparin precursor polysaccha-
ride, O-sulfated K5PS, N-desulfated heparin, and N-desulfated, N-
acetylated heparin were supplied by Dr. G. van Dedem (AKZO-Nobel,
Oss, The Netherlands). N-Sulfated K5PS was a gift from Dr. B. Casu
(Instituto di Chimica e Biochimica G. Ronzoni, Milan, Italy). Porcine
intestinal heparin was from Leo Pharmaceutical Products (Weesp, The
Netherlands).
Biotinylation of HS
HS-II, EHS-HS, and bovine kidney HS were biotinylated by derivat-
ization of the carboxyl groups using biotin LC hydrazide (Pierce Chem-
ical Company) according to the instructions of the manufacturer. HS-II
was also biotinylated via its N-unsubstituted GlcN units using NHS-
LC-biotin (Pierce).
Monoclonal Antibodies
The four murine monoclonal antibodies against HS were all of the
IgM isotype. JM403 was generated by immunization with rat glomer-
ular HS proteoglycans (21), JM13 was obtained from immunization
with human glomerular HS proteoglycans (16), 10E4 by immunization
with liposome-intercalated membrane HS proteoglycans from human
fetal lung fibroblasts (14), and HepSS1 after immunization with murine
methylcholanthrene-induced fibrosarcoma cells (17). The 10E4 and
HepSS1 antibodies are commercially available at Seikagaku Corp.
(www.acciusa.com/seikagaku/products/product.asp).
Immunocytological and Immunohistological Analyses
Embryonic Rat Tissues—Methanol-fixed 10-m cryostat sections of
embryonic rat heads were used for immunohistochemical analysis.
Nonspecific binding sites were blocked by incubating the sections in
PBS containing 1% (w/v) bovine serum albumin and 0.05% (v/v) Tween
20 for 30 min followed by a 40-min incubation with the primary anti-
bodies (diluted 1:10,000). The sections were washed with PBS and
0.05% Tween 20 (three times for 10 min/wash) and incubated for 40 min
with the secondary antibody (Cy3-conjugated goat anti-mouse IgM,
1:600 dilution; Sigma). The slides were again washed with PBS and
Tween as above and mounted with Vectashield mounting medium (Vec-
tor Laboratories). All incubations were performed at room temperature.
The slides were examined using a Zeiss Axiophot microscope.
Human Uterine Cervix—Slide-mounted, paraffin-embedded 6-m
sections of human uterine cervix (generously provided by Dr. Frej
Stenba¨ck, University of Oulu) were pretreated for antigen retrieval2 in
citrate buffer, pH 6.0, in a microwave oven, followed by blocking of
unspecific antibody binding sites with 2% normal horse serum and
incubation with the primary antibodies JM403 (1:10,000), JM13 (1:
20,000), HepSS1 (1:20,000), and 10E4 (1:10,000). The immunoreactivity
was amplified using biotin-conjugated anti-mouse IgM (1:250; Vec-
tastain, Vector Laboratories) and detected with streptavidin-conju-
gated horseradish peroxidase using 3,3-diaminobenzidine tetrahydro-
chloride (Sigma) as substrate. Sections were counterstained with
Meyer’s hematoxylin (Sigma) and examined using an Olympus BX60
microscope. Images were taken with Olympus U-CMAD-2 CCD camera.
Some tissue sections were treated with heparitinase (25 milliunits/
ml; EC 4.2.2.8; Seikagaku Corp.) for 1 h at 37 °C in PBS containing 5
mM calcium acetate to assess the specificity of the staining.
Immunocytochemistry—The cells used for immunostaining included
human embryonic kidney (HEK293) cells, either mock-transfected or
transfected with HS 2-O-sulfotransferase (2-OST), 6-O-sulfotrans-
ferase-3 (6-OST3) (kindly provided by Marion Kusche-Gullberg,
Uppsala), or N-deacetylase/N-sulfotransferase-2 (NDST-2) (a gift from
Lena Kjelle´n, Uppsala) and parental Chinese hamster ovary (CHO)
cells (CHO-K1), the HS-deficient strain (CHO677) and the 2-OST-defi-
cient strain (CHO-F17). The cells were maintained as described previ-
ously (23, 24), fixed with 4% paraformaldehyde, and processed for
indirect immunofluorescence. The primary antibodies were visualized
with fluorescein isothiocyanate-conjugated anti-mouse IgM secondary
antibodies. The coverslips were mounted with Vectashield mounting
medium containing DAPI nuclear stain (Vector Laboratories). Fluores-
cence images were analyzed with Zeiss LSM 510 confocal microscope.
For FACS analysis, HEK293 cells were incubated with the anti-HS
antibodies for 20 min at 4 °C followed by incubation with fluorescein
isothiocyanate-conjugated anti-mouse IgM. The cells were washed
twice and fixed with 1% paraformaldehyde. All incubations and washes
were performed in PBS containing 2% fetal calf serum and 1 nM sodium
azide. The immunoreactivity of the cells was analyzed using a FACS
Calibur instrument (BD Biosciences).
ELISA—The binding of the antibodies to various polysaccharides
was assessed by inhibition ELISA. Two different protocols were used. In
Protocol 1, antibodies were immobilized to polystyrene flat bottom
microtiter plates (Nunc Maxisorp) precoated with goat anti-mouse IgM
antibodies (Sigma). Biotinylated HS-II was added together with in-
creasing concentrations of unlabeled competitor glycosaminoglycans. Bi-
otinylated HS-II remaining on the plates after washes was detected by
peroxidase-labeled streptavidin (Amersham Biosciences) and developed
using 3,3,5,5-tetramethylbenzidine (SFRI Laboratories, Berganton,
France) as peroxidase substrate. The color reaction was stopped with
sulfuric acid, and absorption was measured at 450 nm. In Protocol 2,
biotinylated HS from the EHS tumor was immobilized to streptavidin-
coated plates followed by the addition of antibodies and the competitor
saccharides. Bound antibody was detected using horseradish peroxi-
dase-labeled anti-mouse IgM antibodies using 3,3,5,5-tetramethylben-
zidine as peroxidase substrate. In both protocols, competition was cal-
culated as (1 (A450 with competitor/A450 without competitor)) 100%.
The results from experiments according to Protocol 1 were normalized
relative to the inhibition accomplished by HS-II, which was set to 1.00.
RESULTS
All Four Heparan Sulfate Epitopes Show
Distinct Tissue Localization
Developing Rat Tooth—The four antibodies studied demon-
strated a different pattern of HS staining in the developing rat
molar tooth. The HepSS1 and JM13 epitopes were largely
confined to the basement membrane, whereas JM403 and 10E4
2 Tissue sections were pretreated with trypsin or incubated in a
microwave oven or pressure cooker prior to the immunohistochemical
staining, and the results were compared with similarly stained sections
without pretreatment. Treatment in a microwave oven (10 min) was
employed in further studies because it resulted in distinct antigen
visualization and well preserved tissue architecture.
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staining was seen both in the basement membrane and the
dental epithelium and/or mesenchyme (Fig. 1 and Table I).
JM403 staining was restricted to the epithelium during early
development (embryonic day 15), but at embryonic day 16 a
distinct staining was seen also in the mesenchymal tissue (Fig.
1). The appearance of the mesenchymal JM403 reactivity thus
coincided with the mesenchymal condensation, which reflects
the commencement of active morphogenesis in the mesen-
chyme. By contrast, 10E4 staining was confined to the mesen-
chyme, whereas the dental epithelium remained negative
throughout the development (Fig. 1; embryonic days 17 and 18,
data not shown). The surrounding oral epithelium stained pos-
itively for JM403 but did not contain the 10E4 epitope (Fig. 1).
Tissue sections pretreated with heparitinase were not stained
by any of the antibodies (data not shown).
All four HS epitopes were found in the basement membrane
HS but with marked differences in their occurrence in the oral
versus dental basement membranes. HepSS1 epitope was thus
expressed weakly in the oral basement membrane but strongly
in the dental basement membrane that separates the morpho-
genetically active epithelial and mesenchymal tissues (Fig. 1).
Immunostaining of adjacent tissue sections with JM13 re-
vealed a largely opposite expression pattern, such that intense
expression was seen in the oral basement membrane but faint
expression in the dental basement membrane. The JM403 and
10E4 epitopes were found in both basement membranes, the
former epitope being expressed preferentially in the oral and
the latter in dental basement membrane (Fig. 1). The different
antibodies thus showed distinct reactivities in the dental ver-
sus oral basement membrane and mesenchyme versus
epithelium.
Human Uterine Cervix—We proceeded to immunostain sec-
tions of human uterine cervix to elucidate whether the same
HS epitopes are found in adult human tissue (Fig. 2). Both
JM13 and JM403 showed distinct staining of the basement
membrane but little or no staining in the ectocervical epithe-
lium or in the underlying stroma. By contrast, 10E4 showed
intense cell surface staining at the suprabasal layers of the
stratified squamous epithelium, but no staining in the base-
ment membrane. The human cervix tissue was not immunore-
active to HepSS1 with any of the antigen retrieval procedures
employed in our study. These data suggest different structures
of basement membrane and epithelial cell HSs in adult human
tissue.
Characterization of the Polysaccharide Epitopes
Recognized by the Antibodies
To characterize the saccharide epitopes recognized by the
antibodies, we assessed the ability of different saccharides to
inhibit the binding of biotinylated HS to immobilized anti-HS
antibodies in ELISAs. All four anti-HS monoclonal antibodies
(JM13, HepSS1, 10E4, and JM403) bound efficiently to bio-
tinylated HS-II, a low sulfated HS species from human aorta,
which was used in the first series of ELISA studies made
according to Protocol 1 (see “Materials and Methods”). To com-
pare the binding properties of the antibodies, the results were
normalized by setting the inhibition obtained by unbiotinylated
HS-II to 1.00. The inhibitor saccharides included various bo-
vine HS species, heparin, and K5PS from E. coli, as well as
various derivatives of these saccharides obtained by chemical
modification (Table II). Further assessment (Table III) of the
10E4 epitope specificity was made in a second series of exper-
iments (Protocol 2; see “Materials and Methods”) involving
immobilized EHS-HS, particularly to evaluate the role of GlcN
N-substitution in 10E4 binding (see below).
JM13—None of the bovine HS preparations competed for the
binding of JM13 to biotinylated HS-II, suggesting that the
epitope occurs rarely in HS (Table II). Treatment of HS-II with
HNO2 at pH 1.5 abolished binding, pointing to the presence of
N-sulfate in the JM13 epitope. The finding that treatment of
HS-II with HNO2 at pH 3.9, which cleaves the polysaccharide
at N-unsubstituted GlcN residues, also abolished antibody re-
activity, would reflect the presence of free amino groups in the
JM13 epitope. However, because N-acetylated HS-II bound
JM13 as effectively as native HS-II, it is more likely that
GlcNH3
 residues in HS-II are present vicinal to the JM13
epitope but not a part of the antibody binding site. Removal of
N-acetyl groups from HS-II as well as their replacement with
N-sulfate groups increased JM13 binding, suggesting an inhib-
itory role for the N-acetyl groups in the interaction (Table II).
Alternatively, the finding may also reflect generation of new
epitopes containing either GlcNH3
 or GlcNSO3
 residues.
Experiments with various K5PS derivatives proved useful in
assessing the role of O-sulfates in JM13 binding. Although the
native or N-deacetylated K5PSs did not bind JM13, some re-
activity was obtained with N- or O-sulfated K5PS and very
strong reactivity with O-sulfated K5PS containing either N-
sulfate groups or N-unsubstituted GlcN units (Table II). These
data indicate that O-sulfation is essential for the binding and
confirm the idea that N-acetyl groups inhibit the binding. The
finding that N-deacetylated, O-sulfated K5PS bound JM13
much better than N-deacetylated or N-desulfated heparin sug-
gests that IdoUA units interfere with JM13 binding because
K5PS lacks IdoUA, which is abundant (75% of all hexuronic
acid residues) in heparin. In conclusion, JM13 appears to rec-
ognize a rare HS epitope, characterized by the presence of
O-sulfate substituents in a GlcUA-rich sequence (Table IV).
HepSS1—The HepSS1 epitope was present in bovine aorta
HS but not in other bovine HS preparations (Table II). Treat-
ment of HS-II with HNO2 at pH 1.5 abolished HepSS1 binding,
whereas treatment with HNO2 at pH 3.9 or N-acetylation had
no effect. N-Deacetylation of HS-II abolished the binding, but
FIG. 1. Immunohistochemical localization of HS epitopes in
developing tooth. 10-m cryostat sections of rat molar tooth were
immunostained with HepSS1, JM13, JM403, and 10E4 followed by
detection of the bound antibody with fluorescent secondary antibodies.
E15 and E16 refer to the days 15 and 16 of embryonic development.
The specialized tissue structures shown in the uppermost right panel
are as follows: obm, oral basement membrane; dbm, dental basement
membrane; oe, oral epithelium; de, dental epithelium; dm, dental
mesenchyme.
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increased binding was seen upon subsequent N-sulfation of the
N-deacetylated polysaccharide. All of these findings suggest a
role for the N-sulfate substituents in the binding. Notably, a
functional HepSS1 epitope could be generated solely by exten-
sive (95%) N-deacetylation/N-sulfation of K5PS (Table II).
These findings suggest a role for consecutive GlcUA-GlcNSO3
disaccharide units in the interaction. O-Sulfate groups or
IdoUA did not seem to be involved in HepSS1 binding, as
indicated by experiments with O-sulfated K5PS species or
chemically modified heparin preparations (Table II).
To define the HepSS1 epitope further, we assessed the abil-
ity of EHS-HS and partially N-sulfated K5PSs to bind HepSS1.
Partially (60%) N-sulfated K5PS did not react with HepSS1
(Fig. 3), whereas a completely (95%) N-sulfated preparation
was reactive (Table II). Furthermore, HepSS1 displayed
strong reactivity toward EHS-HS that was shown to contain,
by compositional disaccharide analysis, an unusually high
proportion (60%) of non-O-sulfated HexA-GlcNSO3
 disac-
charide units. Such units are arranged in a consecutive fash-
ion in HS (N-sulfated domains) but not in partially N-sulfated
K5PS in which the chemical N-deacetylation/N-sulfation gives
rise to randomly distributed GlcNSO3
 residues along the
polysaccharide.
10E4—The 10E4 epitope was found in bovine aorta and
intestine HS preparations (Table II). The reactivity was lost by
treatment of HS-II with HNO2 at pH 1.5, suggesting the pres-
ence of N-sulfate substituents in the epitope. Treatment of
HS-II with HNO2 at pH 3.9 resulted in reduced 10E4 binding.
This finding would point to an involvement of GlcNH3
 units,
but because N-substitution of such units by N-acetylation did
not influence the binding, it is more likely that chain breakage
at GlcNH3
 units destroys the 10E4 epitope without GlcNH3

units being an integral part of the antibody recognition site.
Reactivity was lost after N-deacetylation, and it could not re-
stored by subsequent N-sulfation of HS-II. These data suggest
that N-acetyl groups are essential for 10E4 binding.
It has been postulated previously that the 10E4 epitope
would encompass the unsulfated —GlcUA-GlcNH3
-GlcUA-Gl-
cNAc— sequence. Because the initial data from the current
study (Table II) did not support the conclusion that GlcNH3

residues play a role in 10E4 binding, a second set of experi-
ments (Table III) was performed to address further the role of
GlcN N-substitution. For comparison, JM403 was studied in a
similar fashion because earlier data (12, 25) as well as the
results presented here (Tables II and III; see below) indicate a
critical role for GlcNH3
 units in JM403 binding. The results
demonstrated that partially deacetylated K5PS, containing
40% of N-unsubstituted GlcN residues and 60% of N-acety-
lated GlcN residues, bound well to JM403 but failed to react
with 10E4, whereas the 10E4 reactivity was induced upon
N-sulfation of the GlcNH3
 units (Table III). Moreover, two of
three chemically modified preparations of bovine kidney HS
that contained significant proportions (23–39% of all GlcN res-
idues) of GlcNH3
 units lacked 10E4 reactivity, whereas the
same preparations all bound JM403. One preparation (com-
pletely desulfated, N-sulfated, and partially N-deacetylated
HS; Table III) showed some 10E4 reactivity, but the reactivity
was three times weaker than that of an un-N-deacetylated
preparation (Table III). The current data thus support the
conclusion that both N-sulfated and N-acetylated disaccharide
units are required for 10E4 reactivity. Comparison of the reac-
tivities of native and O-desulfated HS as well as partially
N-deacetylated/N-sulfated HS with or without O-sulfation sug-
gests that O-sulfation is not required for 10E4 binding.
JM403—We have demonstrated earlier that JM403 recog-
nizes an epitope with one or more critically important GlcNH3

units (12, 25). The epitope occurred commonly in the bovine HS
preparations because all HS species were recognized by JM403
(Table II). Although native K5PS did not bind JM403, strong
reactivity was obtained by N-deacetylated K5PS. The finding
that the N-deacetylated K5PS was the most efficient inhibitor
of the HS-II-JM403 interaction of all polysaccharides tested
TABLE I
Immunolocalization of anti-HS antibody epitopes in embryonic rat tooth and adult human cervix tissues
Tissue sections of developing rat tooth and human uterine cervix were stained with the anti-HS antibodies. The staining intensity was graded
as follows: , no staining; , weak staining, , moderate staining, , strong staining.
Antibody Dental BMa Oral BM Dental epithelium Oral epithelium Dental mesenchyme Uterine cervix epithelium Uterine cervix BM
HepSS1       
JM13       
JM403       
10E4       
a BM, basement membrane.
FIG. 2. Immunohistochemical localization of HS epitopes in
human uterine cervix. Paraffin-embedded sections (5 m) of human
uterine cervix tissue were subjected to antigen retrieval by treatment in
microwave oven followed by immunostaining with HepSS1, JM13,
JM403, and 10E4, detection by peroxidase-conjugated secondary anti-
bodies, and counterstaining with hematoxylin. The arrow indicates the
basement membrane separating the stratified squamous epithelium of
the ectocervix and the underlying stroma.
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indicates that the N-unsubstituted GlcN units are both neces-
sary and sufficient, in the absence of any other polymer modi-
fication, for JM403 binding. IdoUA units seemed to hamper the
binding because N-/O-desulfated, N-deacetylated heparin did
not function as an efficient inhibitor.
Anti-HS Antibody Immunoreactivity in Cells with Altered HS
Biosynthesis Enzyme Expression—We sought to corroborate
the ELISA data above by assessing the immunoreactivity of the
antibodies in cells with defined alterations in HS composition,
either because of transfectional overexpression of HS biosyn-
thesis enzymes or lack of enzyme activity. HS from human
HEK293 cells overexpressing HS 2-OST (24) thus contains a
TABLE II
Inhibition of the binding of biotinylated HS to immobilized anti-HS antibodies in ELISA (Protocol 1) by various heparin-like polysaccharides
Results are expressed as inhibitory capacity relative to HS-II (set to 1.00).
Inhibitor JM13 HepSS1 10E4 JM403
Derivatives of K5PS
Native K5 0.01 0.01 0.01 0.01
N-Deacetylated K5 0.01 0.01 0.01 7.50
N-Deacetylated, N-sulfated K5 0.50 2.80 0.01 0.01
O-Sulfated K5 2.20 0.01 0.01 0.01
N-Deacetylated, O-sulfated K5 100.00 0.01 0.01 0.03
N-Deacetylated, N-sulfated, O-sulfated K5 100.00 0.01 0.01 0.01
Derivatives of human aorta HS-II
Native HS-II 1.00 1.00 1.00 1.00
HS-II, HNO2, pH 1.5 0.01 0.01 0.01 0.01
HS-II, HNO2, pH 3.9 0.01 1.00 0.10 0.01
N-Acetylated HS-II 1.00 1.00 1.00 0.01
N-Deacetylated HS-II 10.00 0.01 0.01 4.40
N-Deacetylated, N-sulfated HS-II 10.00 5.21 0.01 0.01
Heparan sulfate preparations from bovine organs
Aorta 0.01 0.36 2.56 0.94
Lung 0.01 0.06 0.01 0.77
Intestine 0.01 0.07 6.88 0.91
Kidney (1.1 M) 0.01 0.04 0.01 0.27
Kidney (1.25 M) 0.01 0.01 0.01 0.16
Heparin derivatives
Native heparin 0.01 0.01 0.01 0.01
N-Deacetylated heparin 0.01 0.01 0.01 0.01
N-Desulfated heparin 0.01 0.01 0.01 0.01
N-Desulfated, N-acetylated heparin 0.01 0.01 0.01 0.01
N- and O-desulfated, N-deacetylated heparin 0.01 0.01 0.01 0.05
N- and O-desulfated, N-reacetylated heparin 0.01 0.01 0.01 0.01
N-Resulfated, O-desulfated heparin 0.01 0.01 0.01 0.01
TABLE III
Inhibition of the binding of two anti-HS antibodies to immobilized EHS-HS in ELISA by various HS-related polysaccharides in the fluid phase
Results are expressed as the concentration of inhibitor which gives 50% inhibition in the ELISA system (IC50). The GlcN N-substitution and
degree of 6-O-sulfation of the inhibitor polysaccharides are indicated as a percent of all GlcN residues.
Inhibitor
GlcN substitution
6-O-Sulfate
IC50
N-Acetyl N-Sulfate –NH3
 10E4 JM403
% % % % g/ml g/ml
Derivatives of E. coli K5PS
Native K5 100 0 0 0 100 100
PDeAca K5 59 0 41 0 100 0.004
PDeAc K5 followed by NSb 42 58 0 0 36.4 100
Heparan sulfate
Bovine kidney 65 33 2 25 67.1 5.16
EHS tumor 35 63 2 2 3.0 5.1
Derivatives of HS from bovine kidney
CDSc HS 61 0 39 0 100 4.64
CDS HS followed by NS 62 38 0 2 20.1 100
CDS/NS-HS followed by PDeAc 38 37 25 2 62.9 0.45
CDS/NS/PDeAc/NS HS 39 61 0 4 38.9 100
PDeAc HS 43 34 23 19 100 0.05
PDeAc/NS HS 36 64 0 30 100 100
a PDeAc, partially N-deacetylated.
b NS, N-sulfation.
c CDS, completely desulfated.
TABLE IV
Epitope characteristics of four anti-HS antibodies
Antibody Occurrence in HS Required GlcN N-substitution
Requirement for
Epitope characteristics
O-Sulfate IdoUA
JM13 Rare N-Sulfate or –NH3
 Yes No 2-O-Sulfated GlcUA-rich sequence
HepSS1 Rare N-sulfate No No N-Sulfated GlcUA-rich sequence
10E4 Common N-sulfate and N-acetyl No No Mixed N-acetylated/N-sulfated sequence
JM403 Common –NH3
 No No GlcUA-rich sequences with N-unsubstituted GlcN units
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high proportion of 2-O-sulfated GlcUA units (19% of total hex-
uronic acid residues versus 4% in untransfected cells),
whereas HS from 2-OST-deficient CHO cells (F17) completely
lacks GlcUA(2-OSO3
) (23). Immunostaining of the cells with
JM13 indicated markedly increased reactivity in 2-OST-trans-
fected cells compared with untransfected cells, whereas there
was no staining in 2-OST-deficient cells (Fig. 4A), indicating
that 2-O-sulfated GlcUA units are critical for JM13 binding. In
agreement with this notion, JM13 staining was not altered in
HS 6-OST3- (data not shown) or NDST-2- (26) transfected cells
(Fig. 4A), which show increased GlcN 6-O-sulfation3 and high
proportions of non-O-sulfated GlcUA-GlcNSO3
 disaccharide
units (26), respectively, but do not differ from untransfected
cells in their GlcUA(2-OSO3
) content. The results were con-
firmed by FACS analysis, which demonstrated2-fold increase
in JM13 reactivity (Fig. 5).
In contrast to findings with JM13, the NDST-2-transfected
cells showed intense immunoreactivity to HepSS1 (Fig. 4B), in
agreement with the finding that the HepSS1 epitope contains
consecutive non-O-sulfated HexA-GlcNSO3
 units. FACS anal-
ysis indicated a 5-fold increase compared with mock-trans-
fected cells (Fig. 5). The NDST-2-transfected cells were also
reactive to 10E4 (Figs. 4C and 5), consistent with the finding
that their HS shows increased N-sulfation and decreased O-
sulfation compared with control cells (26), hence higher propor-
tions of non-O-sulfated domains containing both N-sulfated
and N-acetylated disaccharide units. Similar findings, i.e. in-
creased HepSS1 and 10E4 immunoreactivity, were obtained
with the 2-OST-deficient CHO-F17 cells (Fig. 4, B and C) be-
cause these cells also display increased N-sulfation and de-
creased O-sulfation compared with parental CHO-K1 cells (23).
The antibodies did not bind to the HS-deficient CHO677 cells,
indicating that they did not cross-react with chondroitin sulfate
or other cell surface components.
Conclusions—The results of the epitope characterization in-
dicate that the four antibodies recognize different HS epitopes,
which differ in their abundance in isolated HS species, cultured
cells, and tissue specimens. Generally, the results support the
idea that the HepSS1 and JM13 epitopes represent rarely
occurring HS structures (Table IV). They did not bind heparin
and showed little or no binding to HS preparations from bovine
aorta, lung, intestine, and kidney. At the tissue level, their
expression was confined to the basement membrane HS. By
contrast, the 10E4 and JM403 epitopes seemed to occur more
commonly in preparations of purified bovine HS as well as in
tissues. However, the epitopes were not found in heparin. 10E4
thus recognized both aorta and intestine HS, and JM403
showed some binding to all HS species tested. JM13 was the
only antibody that required O-sulfate substituents for its bind-
ing, presumably in the form of 2-O-sulfated GlcUA residues.
HepSS1 recognized N-sulfated disaccharide sequences in HS,
whereas O-sulfation had an inhibitory role. The JM403 epitope
contains an essential GlcNH3
 residue, in accordance with our
earlier findings (12). The 10E4 epitope appears to involve both
N-sulfated and N-acetylated disaccharide constituents of HS,
whereas O-sulfate groups are not required for 10E4 binding.
All four antibodies seemed to bind to GlcUA-containing se-
quences, whereas IdoUA units did not appear to have a role in
their epitope recognition.
DISCUSSION
It is thought that specialized domain structures in HS can
modulate the functions of various effector proteins. The eluci-
dation of such structures has been pursued by biochemical
methods employing isolated HS oligosaccharides, which, how-
ever, have to be purified close to homogeneity to allow detailed
analysis such as sequencing (7, 27–29). Although these tech-
niques provide detailed data of HS structure they do not yield
information on the localization of domains in tissues because
the “HS starting material” unavoidably represents a mixture of
different HS species. On the other hand, protein binding stud-
ies made in situ with cultured cells or tissue specimens have
provided useful in assessing the localization of functional HS
domains (11, 30), but structural information is not readily
obtained. Antibodies recognizing structurally defined HS
epitopes should therefore represent a useful complement to
other methods of HS analysis. Detection of HS by monoclonal
antibodies is used increasingly in studies addressing the role of
the polysaccharide in various biological phenomena and its
distribution in cells and tissues. Because of the complex and
highly variable structure of HS, such antibodies likely recog-
nize specific epitopes that may be present in some HS species
and absent in others instead of recognizing ubiquitous HS
structures. This assumption is particularly relevant for anti-
bodies raised by immunization of animals with HS because the
most commonly occurring saccharide structures are not likely
to elicit an immune response. The general structural features
of HS are the same among a number of HS preparations from
different cell and tissue sources, and they seem to be shared by
a variety of animal species. By contrast, antibodies generated3 M. Kusche-Gullberg, personal communication.
FIG. 3. HepSS1 binds to EHS-HS containing GlcUA-GlcNSO3

sequences with a low degree of O-sulfation. A, disaccharide com-
position of HS from EHS tumor and bovine kidney. Note the high
proportion ofN-sulfated, non-O-sulfated disaccharides (HexA-GlcNS) in
EHS-HS and the low proportion of such units in BK-HS. B, inhibition of
HepSS1 binding to immobilized EHS-HS by BK-HS, EHS-HS, and
partially N-deacetylated K5PS with (PNDAc/NS) or without (PDNAc)
N-sulfation of the GlcN units. The ability of the saccharides to inhibit
HepSS1 binding to biotinylated EHS-HS was assessed by the ELISA
Protocol 2 (see “Materials and Methods”).
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by the phage display technique do not depend on the host
immune response and may conceivably bind any HS structure
regardless of the frequency of its occurrence in natural HS
species. The results of Dennissen et al. (13) support this view by
demonstrating that many generally occurring saccharide struc-
tures found in HS and heparin were recognized by the phage
display antibodies.
Polysaccharides are generally regarded as poor immuno-
gens. It is of note that all four antibodies characterized here are
of the IgM isotype, the pentameric structure of which might
enable multivalent binding to a polymeric antigen such as HS. It
is possible that polyvalent binding is required to entail sufficient
binding avidity if the binding of an individual Fc moiety to the
antigen is weak. According to this hypothesis, the binding of an
IgM antibody to HS would require the presence of multiple bind-
ing sites conforming to the cognate epitope structure of the anti-
body, perhaps with appropriate spacing along the HS polymer.
Results from the JM13 epitope characterization point to an
important role ofO-sulfation together with GlcUA residues and
either N-sulfated or N-unsubstituted GlcN units. In JM13-
reactive HS, such O-sulfate groups may reside either in the 2-O
position of the GlcUA residues or as 6-O-sulfated GlcN units.
Although it was difficult to differentiate between these possi-
bilities by the ELISAs (because of the lack of sufficiently spe-
cific competitor saccharides), the immunostaining experiments
with cells showing either increased 2-O- or 6-O-sulfation or
lack of 2-O-sulfate clearly indicated that the critical structural
determinant for JM13 binding is 2-O-sulfated GlcUA. 3-O-
Sulfated GlcN units are not likely to be a part of the JM13
epitope because human aorta HS was highly reactive with
JM13 but lacks 3-O-sulfation (31).
Several lines of evidence suggest a critical role for consecu-
tive, non-O-sulfated GlcUA-GlcNSO3 disaccharide units in
HepSS1 binding. First, the epitope was generated by extensive
but not partial N-sulfation of N-deacetylated K5PS. Second,
the antibody bound to aorta HS, which is rich in N-sulfate but
FIG. 4. Immunocytochemical analysis of antibody binding to cells with altered HS structure. Mock-transfected (mock), 2-OST-
transfected, or NDST-2-transfected HEK293 cells and parental CHO cells (K1), HS-deficient CHO677, cells and 2-O-sulfate-deficient CHO-F17
cells were grown on glass coverslips, immunostained with JM13 (a), HepSS1 (b), 10E4 (c), and JM403 (d) and analyzed by confocal microscopy. The
immunoreactivity appears in green and the nuclear DAPI stain in blue. Note the high JM13 immunoreactivity in 2-OST-transfected HEK293 cells
and lack of immunoreactivity in 2-O-sulfate-deficient cells.
FIG. 5. FACS analysis of antibody
binding to sulfotransferase-trans-
fected HEK293 cells. The cells were
stained with the various antibodies (as
indicated in each panel) and analyzed by
FACS. The immunoreactivity intensities
(measured as mean fluorescence inten-
sity) are expressed as setting the immu-
noreactivity of the mock-transfected
HEK293 cells to 1.
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has a low degree of O-sulfation (19, 31), and N-deacetylation/
N-sulfation of the polysaccharide further increased its HepSS1
reactivity. Third, HepSS1 showed strong reactivity with HS
from the EHS tumor that contains an unusually high propor-
tion of GlcUA-GlcNSO3 disaccharide units (60%; Fig. 3), and
NDST-2-transfected cells expressing HS with high proportions
of such units displayed increased immunoreactivity.
The results reported by Leteux et al. (15) suggested that the
10E4 antibody recognizes a HS tetrasaccharide with the struc-
ture —GlcUA-GlcNH3
-GlcUA-GlcNAc—. The N-unsubstituted
GlcN residue appeared to have a critical role in the sequence
because tetrasaccharides with GlcNSO3
 or GlcNAc residues in
the same position failed to react with 10E4. In our studies, the
preferred epitope seemed to contain both N-sulfated and N-
acetylated disaccharide units, whereas no direct role for the
GlcNH3
 residues could be demonstrated. The same conclusion
can also be drawn from the recent study of Cheng et al. (25) in
which N-acetylation of HS in cultured bladder carcinoma cells
did not affect 10E4 reactivity, whereas JM403 binding was lost.
The results of the current study further show that 10E4 did not
bind completely or partially N-deacetylated K5PS and that
N-acetylation of HS-II did not affect its 10E4 reactivity. How-
ever, deaminative cleavage of HS-II at its GlcNH3
 residues
resulted in reduced reactivity, suggesting that in native HS the
10E4 epitope may be found vicinal to theN-unsubstituted GlcN
units and that such units are tolerated within the epitope (32).
Because the HS derivatives with both N-sulfated and N-acety-
lated disaccharide units all reacted with 10E4, whereas those
containing only a single type of N-substitution did not, we
conclude that a mixed N-sulfated/N-acetylated epitope is re-
quired for 10E4 binding.
Previous studies suggest that 6-O-sulfated GlcN residues
may play a role in 10E4 recognition. The extracellularly acting
6-O-endosulfatase QSulf1 thus reduces 10E4 staining (33) in
cultured cells, and treatment of cultured mouse embryos with
sodium chlorate, a metabolic inhibitor of sulfation, diminishes
10E4 reactivity in the developing spinal cord (34). Chlorate
treatment preferentially affects O-sulfation, especially the 6-O-
sulfation of GlcN residues, rather than N-sulfation (35). The
results of the current study do not support these views because
cells with increased 6-O-sulfation showed weak 10E4 reactivity
(data not shown), whereas increased reactivity was seen in
NDST-2-transfected cells in which glucosaminyl N-sulfation is
increased with concomitant decrease of O-sulfate substitution.
In agreement with our previous findings, the current study
points to the critical role of the GlcNH3
 residues in JM403
binding. Modification of K5PS by complete or partial
N-deacetylation thus generated polysaccharides that bound
JM403 more efficiently than any other preparation tested, in-
dicating that the —GlcUA-GlcNH3
— structure is sufficient for
efficient JM403 binding. It is of note that JM403 reactivity was
decreased in NDST-2-transfected cells because the increased
N-sulfotransferase activity likely reduces the number of free
amino groups.
The developmental processes are critically dependent on the
spatially and temporally controlled activity of morphogenic
proteins (22, 36, 37). Because many such proteins exert their
action at distance from the site of their synthesis, there have to
be mechanisms to control not only the expression but also the
subsequent tissue localization of the proteins. Tooth develop-
ment is a well characterized example of organ formation
through interactions of the ectodermal epithelium and neural
crest-derived mesenchyme. Such interactions require that mol-
ecules synthesized in one tissue compartment (epithelium or
mesenchyme) and exerting their action in the other must tra-
verse the cellular and basement membrane structures separat-
ing the sites of production and action. For example, epithelial
signaling molecules such as FGF8 and bone morphogenetic
protein 4 have been shown to regulate gene expression in the
mesenchymal cells, and mesenchymally produced FGFs stim-
ulate FGF receptor-expressing cells in the epithelium (37). It is
interesting to note that the dental basement membrane HS
stained positively for antibodies that recognize epitopes with
N-sulfation orN-unsubstituted GlcN residues, but no O-sulfate
groups, whereas the basement membrane HS of human uterine
cervix contained the O-sulfated JM13 epitope. The HS found in
the embryonic basement membrane may be more permissive to
the molecular traffic between the epithelial and mesenchymal
tissues than more highly O-sulfated HS species.
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